ArticlePopulation health metrics2026
Reimagining COVID vaccine distribution: reflecting on waste and equity.
Article in Population health metrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundEfficient distribution and administration of vaccines are critical to preventing unnecessary morbidity and mortality. We assess the distribution, uptake, and wastage of COVID-19 vaccine doses across the U.S., providing insights for optimizing future vaccination distribution strategies. We quantify the impact of limiting vaccine wastage and illustrate incidence and deaths averted under two targets set by the Global Alliance for Vaccines and Immunization (GAVI).
methodsWe obtained COVID-19 vaccine doses administered by location and wastage data from jurisdictions, pharmacies, and federal entities from the Centers for Disease Control and Prevention through a Freedom of Information Act. From this data, along with county-level data on COVID-19 vaccine hesitancy, we conducted a retrospective analysis covering the period from December 2020 to October 2022 involving 761 million vaccine doses distributed across all counties and states in the U.S. We use GAVI targets of 25% and 15% vaccine waste to serve as benchmarks for assessing the impact of potential improvements in vaccine distribution and acceptance at the county and state levels in the U.S.
resultsWe estimate the proportion of vaccines wasted, and then incidence and deaths averted had adherence to GAVI waste targets occurred to inform on the quality of the national vaccination effort and identify potential regions for improvement. Among the 761 million distributed COVID-19 vaccine doses, only 600 million were administered, resulting in a national average of 1.8 doses per capita. Substantial regional disparities were observed, with the District of Columbia reaching 2.5 doses per capita and Alabama lagging at 1.3 doses per capita. Thirty states exceeded the GAVI 15% vaccine waste target, corresponding to 64.2 million unused doses. Meeting the 15% target would have averted 36.1 million incidences and 7.8 thousand deaths.
conclusionsAddressing the causes of county-level variations and targeting states with below-average vaccine hesitancy and above-target vaccine waste would likely maximize future vaccine distribution efforts and minimize wastage-related losses. This strategy highlights an avenue for improving future vaccine distribution policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.